Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NeutriSci International Inc V.NU.H

Alternate Symbol(s):  NRXCF

NeutriSci International Inc. (NeutriSci) is a Canada-based company, which specializes in the production, and formulation of nutraceutical products within the business-to-business (B2B) industry. The Company is focused on the market development for its nutraceutical products. Its products utilize patented form of Pterostilbene called pTeroPure. pTeroPure Pterostilbene is a form of all-trans Pterostilbene that is found naturally in blueberries and is manufactured for NeutriSci by ChromaDex Corp. (ChromaDex) in the United States. NeutriSci’s neuenergy product is an energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash that is associated with energy products. It has developed proprietary IP and technology (NeutriSci IP) that creates an efficient method of bilingual absorption of nutraceuticals into the bloodstream. NeutriSci’s IP can be applied to many different categories in the beverage, food, and nutraceutical space.


TSXV:NU.H - Post by User

Comment by Edcandoon Jul 07, 2021 10:00pm
121 Views
Post# 33510261

RE:RE:RE:RE:Latest nr

RE:RE:RE:RE:Latest nr

  Well that would certainly be an interesting turn of events. But the NR doesn't say that either. For 100%, pac west is also our partner for the beverage line that already  has 2 X 500k unit POs (an initial  with a follow up same customer) while the delta 8 just finished R&D so it actually makes more sense it would be for the beverage sku as there's already an order? Delta 8 or beverage makes no difference. The point still stands that it wasn't changing the Tabletz narrative where we already have an aprroved package design (and most likely a bunch of extra packages since you wouldn't just ship small batches of packaging from China lol.  Regardless I'm glad you brought that up. Just highlighting another potential revenue stream.  The beauty of our business model is it doesn't matter really matter too much if  delta 8 has a lasting place in market or just a fad (besides the obvious fact that each product that succeeds and lasts long time means longer recurring revenues).  It is our IP and ingredients not our branding. Revenue is revenue. If we produce /sell a bunch of delta 8 for a year or 2 and it fades out then we had delta 8 revenues (with no delta 8 specific costs) for a year or 2 lol. Really we just need this final execution. Ship the  initial order and get a few more smoothly under our belts to show consistency and bibs your uncle. 


sundial growers: not profitable / trading 7X sales
Canopy : not profitable / trading 20 x  sales 
Cronos : not profitable / trading 58 x sales 

Tell me again how we aren't undervalued? Yes it isn't the best metric to showcase  bloated overvalued pigs as a comparative , but in this case it isn't the worst . There are so many other examples with far too much forward thinking baked in to today's price. Yet here we sit with a decent chance of ending the year with $10-$14-$20+ million (even with all the annoying delays) . Wherever we fall it will be on good margins with no toxic debt, minimal overhead, and it will be 90%-95% from just a handful of orders for one deal in one country for one product (and only about 6 months of shipping). That description is the exact thing that justifies trading at multiples much higher than I've ever used for us. The reason is simply a combination of legitimacy and the existing room for explosive potential growth. If we do get let's say $10 mil revs this year (really more like 6 months) that wouldn't only be like 80x our highest ever sales (at good margins ) but it would also mean that just with those locations to date (by end of year) we should be able to double that in 2022 (12 months instead of 6 and allowing for no growth in sales or added locations/countries). Literally all that needs to happen now is execution and that our products are well received.   IMO the risk/reward ratio here is something that doesn't come around every day.  Frustrated yet confident . GLTUA
 

<< Previous
Bullboard Posts
Next >>